Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 infant study of Novartis recombinant meningococcal B vaccine with or without OMV-NZ
2006-001522-84Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, meningococcal meningitis and meningococcemia (2 arms), sponsored by Novartis. Started May 2006; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal diseasemeningococcal meningitismeningococcemia
Beyond the preview
Go deeper on 2006-001522-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001522-84.